Paul Léophonte
University of Toulouse
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paul Léophonte.
The Annals of Thoracic Surgery | 2003
Julien Mazieres; M. Murris; A. Didier; Jacques Giron; Marcel Dahan; Jean Berjaud; Paul Léophonte
BACKGROUND Some patients exhibiting severe multisegmental bilateral bronchiectasis are no longer improved with antibiotic treatment and drainage and, most of the time, operation is contraindicated. In our institution, limited operation has been offered to select patients for this indication. We report our data regarding the feasibility and utility of such a procedure. METHODS We studied 16 patients who underwent surgical removal of nonlocalized disease between 1990 and 1999. We report the mortality and morbidity rates of this surgical procedure and the clinical, bacteriological, and functional data for each patient. RESULTS There was no mortality and the morbidity was low (18%, all with favorable outcome). Symptoms such as hemoptysis, sputum production, or dyspnea were also improved. The recurring infections decreased in frequency in 8 patients and disappeared completely in 5 others. The bacteriological data assessment revealed disappearance of germs in 4 patients and persistence of chronic colonization in others. Postoperative spirometric data were not worsened and postoperative computed tomographic scans did not show progression of lesions not removed. CONCLUSIONS These results suggest that, in properly selected patients, lasting symptomatic improvement can be achieved by resection. Limited operation may be indicated in nonlocalized bilateral bronchiectasis, provided that a target can be identified. This procedure is supported by physiopathologic arguments and is particularly relevant to patients with bronchiectasis with cystic and functionless territories.
BMC Pulmonary Medicine | 2015
K. Sedkaoui; Ludivine Leseux; Sandrine Pontier; Nicole Rossin; Paul Léophonte; Jean-Louis Fraysse; Alain Didier
BackgroundContinuous Positive Airway Pressure (CPAP) remains the reference treatment for moderate to severe forms of the Sleep Apnea/Hypopnea Syndrome (SAHS). Compliance to the treatment appears to be a key factor to improving health status of these patients.MethodsWe conducted a multicenter, prospective, randomized, controlled, parallel group trial of standard support completed or not within 3 months of coaching sessions for newly diagnosed SAHS patients starting CPAP therapy. This study has been recorded by AFSSAPS with the RCB number: 2009-A01127-50 and received favourably by the Human Studies Committee in France. The coaching session consisted of 5 sessions of telephone-based counselling by competent staff. The primary outcome was the proportion of patients using CPAP more than 3 h per night for 4 months; the secondary outcome was mean hours of CPAP usage in the 2 groups.ResultsThree hundred and seventy-nine patients fulfilled the inclusion criteria and were randomized. The percentage of patients using CPAP more than 3 h per night for 4 months was 65 % for the standard support group and 75 % for the coached group. This difference reached a statistical significance (χ2 = 3.97). The mean CPAP usage was increased in the coached group versus standard group. A difference of 26 min was observed (4 h34+/−2 h17 and 4 h08+/−2 h25 respectively, p = 0.04).ConclusionThis study shows that SAHS patients who benefit from phone coaching are statistically more compliant to CPAP than a standard support group is. A simple phone coaching procedure based on knowledge of the disease and reinforcement messages about treatment benefits helps to improve CPAP adherence in SAHS patients.Trial registrationNCT02435355
European Respiratory Journal | 1996
Simon Martel; Philippe Carré; G Carrera; B Pipy; Paul Léophonte
Recurrence of sarcoidosis in lung allografts is an interesting model to study the pathogenesis of this disease. We report a case of sarcoidosis recurrence in a single lung allograft recipient 2 years after transplantation. The expression of tumour necrosis factor-alpha (TNF-alpha) gene by alveolar macrophages was monitored. The TNF-alpha gene was not expressed at the time of recurrence of sarcoidosis, but only later when prominent granulomas were observed.
Chest | 1994
Philippe Carré; Hervé Rousseau; Laurent Lombart; Alain Didier; Marcel Dahan; Gérard Fournial; Paul Léophonte
La Revue du praticien | 2003
Paul Léophonte; Julien Mazieres
Chest | 1994
Philippe Carré; Hervé Rousseau; Laurent Lombart; A. Didier; Marcel Dahan; Gérard Fournial; Paul Léophonte
Chest | 1994
Philippe Carré; Hervé Rousseau; Laurent Lombart; Alain Didier; Marcel Dahan; Gérard Fournial; Paul Léophonte
The American review of respiratory disease | 1990
Philippe Carré; Alain Didier; Bernard Pipy; Marie F. Forgue; Maryse Beraud; Emmanuel P. Meeus; Anne L. Caratero; Paul Léophonte
The Lancet | 1993
M. Murris-Espin; Alain Didier; Philippe Carré; Josette Icart; Sabine Henry; Paul Léophonte
Clinical Microbiology and Infection | 1998
Paul Léophonte; M. Murris-Espin; Alain Berthier; Maxime Dayan